Oxaliplatin Kabi

Oxaliplatin, the active ingredient in Oxaliplatin Kabi, is a platinum-based antineoplastic agent presented as a sterile powder for intravenous infusion use. It is employed in the treatment of colorectal cancer and other gastrointestinal malignancies in adult patients. GNH USA supplies Oxaliplatin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Oxaliplatin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin Kabi is used in colorectal cancer treatment pathways and related gastrointestinal malignancies.

- Colorectal cancer: enhances disease control when combined with fluoropyrimidine-based chemotherapy. - Gastric cancer: contributes to tumor response in combination regimens. - Pancreatic cancer: used as part of multi‑drug protocols to improve response rates. - Advanced solid tumours: employed off‑label in clinical trials for various solid tumours.

Oxaliplatin Kabi may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Diarrhea: watery stools that may require supportive care. - Fatigue: generalized tiredness affecting daily activities. - Myelosuppression: reduced blood cell counts, increasing infection risk. - Elevated liver enzymes: transient changes in hepatic function tests.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis or bronchospasm. - Acute neurotoxicity: sudden onset of muscle cramps or spasms. - Hemolytic anemia: destruction of red blood cells. - Thrombotic events: blood clot formation in veins or arteries. - Cardiotoxicity: arrhythmias or reduced cardiac output. - Renal impairment: acute kidney injury requiring monitoring.

When handling Oxaliplatin Kabi, clinicians should observe specific safety measures and patient monitoring guidelines.

- Renal function: assess baseline creatinine and monitor during therapy. - Hepatic function: evaluate liver enzymes before and throughout treatment. - Neuropathy risk: monitor for sensory changes and adjust dosing if needed. - Myelosuppression: perform regular complete blood counts. - Pregnancy and lactation: avoid use unless benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Oxaliplatin Kabi can interact with several concomitant medications, influencing efficacy or toxicity.

Major Interactions (Avoid): - Nephrotoxic agents: concurrent use may exacerbate renal injury. - Highly protein‑bound drugs: may displace oxalivated   

Moderate   g   t   t   t  : - Anticoagulants: increased bleeding risk; monitor coagulation parameters. - Antiemetics with serotonergic activity: potential for serotonin syndrome. - CYP‑C   t   t  t   t   t  : - Drugs   t   t   t  ":   t  t  t  t  """